Subscribe

Subscribe

Latest Content

Solar

Storage

Wind

Event Spotlight

BLOGS

DISTRIBUTECH+ RECAP: Energy Storage Utility Case Studies

Webcast

OPINION

RESOURCES

CLARION ENERGY MEDIA

POWER & ENERGY EVENT SERIES

Privacy Policy

Copyright © 2019 - 2021

Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Glaukos Corp (NY: GKOS )

111.65 -0.95 (-0.84%)
Streaming Delayed Price Updated: 3:12 PM EDT, Jun 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Glaukos Corp

< Previous 1 2 3 4 5 Next >
Deep Dive Into Glaukos Stock: Analyst Perspectives (12 Ratings)
Via Benzinga
Eye Disease-Focused Glaukos' 'Investor Interest Should Continue To Gain Momentum:' Analyst
Glaukos reports Q1 adjusted EPS loss, sales beat estimates. Strong guidance for 2024 with positive analyst sentiment, driving stock up 6.22%. 
Via Benzinga
Topics Earnings
Exposures Financial
C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday
Via Benzinga
GKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q1 2024
GKOS stock results show that Glaukos missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Analyst Ratings For Glaukos
Via Benzinga
5 Analysts Have This To Say About Glaukos
Via Benzinga
Glaukos: Q4 Earnings Insights
Via Benzinga
Earnings Scheduled For February 21, 2024
Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million. 
Via Benzinga
Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Analyst Ratings For Glaukos
Via Benzinga
Glaukos' Newly Approved Glaucoma Treatment Is The 'Biggest Driver To Watch': Analyst
Shares of Glaukos Corp (NYSE: GKOS) continued to climb in early trading on Thursday, after the company’s iDose TR (travoprost intracameral implant) received U.S. 
Via Benzinga
Unveiling 7 Analyst Insights On Glaukos
Via Benzinga
Analyst Ratings for Glaukos
Via Benzinga
4 Analysts Have This to Say About Glaukos
Via Benzinga
8 Analysts Have This to Say About Glaukos
Via Benzinga
Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
iDoseTR Approval Sets Stage for Glaukos' Game-Changing Product, Surpassing Market Expectations, Says Analyst
Thursday, the FDA approved Glaukos Corporation's (NYSE: GKOS) marketing application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog... 
Via Benzinga
Exposures Product Safety
Dow Extends Rally As Treasury Yields Tank
The Dow Jones Industrial Average is charging full speed ahead, up 78 points this afternoon after yesterday closing at record highs, on the heels of the Federal Reserve's rate decision. 
Via Talk Markets
Topics Economy Stocks
Exposures Interest Rates US Equities
FDA Approves Glaukos' Eye Implant To Treat Eye Pressure In Glaucoma Patients
The FDA approved Glaukos Corporation's (NYSE: GKOS) marketing application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for... 
Via Benzinga
Exposures Product Safety
Glaukos's Earnings Outlook
Via Benzinga
Analyst Ratings for Glaukos
Via Benzinga
Where Glaukos Stands With Analysts
Via Benzinga
Stifel Maintains Buy Rating for Glaukos: Here's What You Need To Know
Via Benzinga
Glaukos Poised To Surpass Expectations And Raise Outlook In Q2 FY23, Fueled By iStent And iAccess Launches: Analyst
Needham expects Glaukos Corp (NYSE: GKOS) to surpass expectations and raise outlook in Q2 FY23, fueled by rebounding iStent inject volumes post-2022 reimbursement-driven declines. An additional upside... 
Via Benzinga
These 2 Soaring Stocks Finished the Week Strong
Wall Street coasted into the close on Friday but still had a good week. 
Via The Motley Fool
UnitedHealth, Elanco Animal Health And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
8 Analysts Have This to Say About Glaukos
Via Benzinga
Glaukos Poised for $1B in Sales by 2030: Piper Sandler Predicts With Stock Upgrade
Piper Sandler has upgraded Glaukos Corporation (NYSE: GKOS) to Overweight from a Neutral ra 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2023
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.